Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.
Gaucher disease (GD) patients often present with abnormalities in immune response that may be the result of alterations in cellular and/or humoral immunity. However, how the treatment and clinical features of patients impact the perturbation of their immunological status remains unclear. To address...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5152900?pdf=render |
| _version_ | 1818923001052135424 |
|---|---|
| author | Renuka Pudi Limgala Chidima Ioanou Matthew Plassmeyer Mark Ryherd Lina Kozhaya Lauren Austin Cem Abidoglu Derya Unutmaz Oral Alpan Ozlem Goker-Alpan |
| author_facet | Renuka Pudi Limgala Chidima Ioanou Matthew Plassmeyer Mark Ryherd Lina Kozhaya Lauren Austin Cem Abidoglu Derya Unutmaz Oral Alpan Ozlem Goker-Alpan |
| author_sort | Renuka Pudi Limgala |
| collection | DOAJ |
| description | Gaucher disease (GD) patients often present with abnormalities in immune response that may be the result of alterations in cellular and/or humoral immunity. However, how the treatment and clinical features of patients impact the perturbation of their immunological status remains unclear. To address this, we assessed the immune profile of 26 GD patients who were part of an enzyme replacement therapy (ERT) study. Patients were evaluated clinically for onset of GD symptoms, duration of therapy and validated outcome measures for ERT. According to DS3 disease severity scoring system criteria, they were assigned to have mild, moderate or severe GD. Flow cytometry based immunophenotyping was performed to analyze subsets of T, B, NK, NKT and dendritic cells. GD patients showed multiple types of immune abnormalities associated to T and B lymphocytes with respect to their subpopulations as well as memory and activation markers. Skewing of CD4 and CD8 T cell numbers resulting in lower CD4/CD8 ratio and an increase in overall T cell activation were observed. A decrease in the overall B cells and an increase in NK and NKT cells were noted in the GD patients compared to controls. These immune alterations do not correlate with GD clinical type or level of biomarkers. However, subjects with persistent immune alterations, especially in B cells and DCs correlate with longer delay in initiation of ERT (ΔTX). Thus, while ERT may reverse some of these immune abnormalities, the immune cell alterations become persistent if therapy is further delayed. These findings have important implications in understanding the immune disruptions before and after treatment of GD patients. |
| first_indexed | 2024-12-20T02:02:29Z |
| format | Article |
| id | doaj.art-6a7e07c2268f41acb2125d2f1d52a418 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T02:02:29Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-6a7e07c2268f41acb2125d2f1d52a4182022-12-21T19:57:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016813510.1371/journal.pone.0168135Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.Renuka Pudi LimgalaChidima IoanouMatthew PlassmeyerMark RyherdLina KozhayaLauren AustinCem AbidogluDerya UnutmazOral AlpanOzlem Goker-AlpanGaucher disease (GD) patients often present with abnormalities in immune response that may be the result of alterations in cellular and/or humoral immunity. However, how the treatment and clinical features of patients impact the perturbation of their immunological status remains unclear. To address this, we assessed the immune profile of 26 GD patients who were part of an enzyme replacement therapy (ERT) study. Patients were evaluated clinically for onset of GD symptoms, duration of therapy and validated outcome measures for ERT. According to DS3 disease severity scoring system criteria, they were assigned to have mild, moderate or severe GD. Flow cytometry based immunophenotyping was performed to analyze subsets of T, B, NK, NKT and dendritic cells. GD patients showed multiple types of immune abnormalities associated to T and B lymphocytes with respect to their subpopulations as well as memory and activation markers. Skewing of CD4 and CD8 T cell numbers resulting in lower CD4/CD8 ratio and an increase in overall T cell activation were observed. A decrease in the overall B cells and an increase in NK and NKT cells were noted in the GD patients compared to controls. These immune alterations do not correlate with GD clinical type or level of biomarkers. However, subjects with persistent immune alterations, especially in B cells and DCs correlate with longer delay in initiation of ERT (ΔTX). Thus, while ERT may reverse some of these immune abnormalities, the immune cell alterations become persistent if therapy is further delayed. These findings have important implications in understanding the immune disruptions before and after treatment of GD patients.http://europepmc.org/articles/PMC5152900?pdf=render |
| spellingShingle | Renuka Pudi Limgala Chidima Ioanou Matthew Plassmeyer Mark Ryherd Lina Kozhaya Lauren Austin Cem Abidoglu Derya Unutmaz Oral Alpan Ozlem Goker-Alpan Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLoS ONE |
| title | Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. |
| title_full | Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. |
| title_fullStr | Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. |
| title_full_unstemmed | Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. |
| title_short | Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. |
| title_sort | time of initiating enzyme replacement therapy affects immune abnormalities and disease severity in patients with gaucher disease |
| url | http://europepmc.org/articles/PMC5152900?pdf=render |
| work_keys_str_mv | AT renukapudilimgala timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT chidimaioanou timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT matthewplassmeyer timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT markryherd timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT linakozhaya timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT laurenaustin timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT cemabidoglu timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT deryaunutmaz timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT oralalpan timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease AT ozlemgokeralpan timeofinitiatingenzymereplacementtherapyaffectsimmuneabnormalitiesanddiseaseseverityinpatientswithgaucherdisease |